BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lenacapavir (Sunlenca) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lenacapavir (Sunlenca)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06749054-966@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Lenacapavir (Sunlenca): Phase 2 readout est. (NCT06749054)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 2\, HIV.\nStudy: Evaluation of L
 ong-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced
  Adolescents and Children\nEstimated primary completion: March 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/lenacapavir-sunlenca#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06749054
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841990-966@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenacapavir (Sunlenca): Phase 2 readout est. (NCT07841990)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 2\, HIV.\nStudy: Substudy-01: A 
 Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 
 With Undetectable Virus Levels\nEstimated primary completion: August 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/lenacapavir-sunlenca
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 41990
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645287-966@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenacapavir (Sunlenca): Phase 2 readout est. (NCT07645287)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 2\, HIV.\nStudy: A Study of GS-3
 242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppr
 essed People With HIV-1\nEstimated primary completion: August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/lenacapavir-sunlenca#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07645287
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518914-966@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Lenacapavir (Sunlenca): Phase na readout est. (NCT07518914)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase na.\nStudy: Protecting Against L
 enacapavir Misinformation With Young Women in Gauteng\, South Africa ( PRO
 TECT-L)\nEstimated primary completion: April 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07518914
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908446-966@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Lenacapavir (Sunlenca): Phase 4 readout est. (NCT07908446)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 4\, HIV.\nStudy: Study of BIC/LE
 N FDC Versus Stable Baseline Regimens in Virologically Suppressed People W
 ith HIV\nEstimated primary completion: July 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07908446
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819176-966@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Lenacapavir (Sunlenca): Phase 1 readout est. (NCT06819176)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 1\, HIV.\nStudy: Lenacapavir Int
 ensification to Disrupt HIV Reservoirs in Virologically Suppressed People 
 With HIV Receiving Antiretroviral Therapy\nEstimated primary completion: 1
  September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lena
 capavir-sunlenca#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06819176
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683000-966@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Lenacapavir (Sunlenca): Phase 3 readout est. (NCT07683000)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 3\, HIV.\nStudy: Study of Lenaca
 pavir\, Teropavimab\, and Zinlirvimab in Virologically Suppressed Adults W
 ith HIV-1 on Stable Oral Treatment Regimens\nEstimated primary completion:
  March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenacapa
 vir-sunlenca#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07683000
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07682961-966@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Lenacapavir (Sunlenca): Phase 3 readout est. (NCT07682961)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 3\, HIV.\nStudy: Study of Lenaca
 pavir\, Teropavimab\, and Zinlirvimab Versus Cabotegravir and Rilpivirine 
 in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral
  Therapy\nEstimated primary completion: March 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07682961
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07939529-966@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Lenacapavir (Sunlenca): Phase 1 readout est. (NCT07939529)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 1\, HIV.\nStudy: People With Act
 ive Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effe
 ctiveness\nEstimated primary completion: 31 August 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07939529
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07708727-966@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Lenacapavir (Sunlenca): Phase 2/3 readout est. (NCT07708727)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 2/3\, HIV.\nStudy: Study of an I
 njectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in Peop
 le New to HIV-1 Treatment\nEstimated primary completion: October 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lenacapavir-sunlenca#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0770872
 7
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
